Computer-aided detection (CAD) software developer VuCOMP has sold off its M-Vu Breast Density software to fellow CAD firm iCAD.
Under the purchase and sale agreement, VuCOMP will transfer its breast density technology and associated service contracts to iCAD. VuCOMP will continue to sell the breast density software, however, and also retain its CAD platform, according to the vendor. The companies will work together to transition service and support for existing M-Vu Breast Density customers over to iCAD, VuCOMP said. Financial terms of the deal were not disclosed.
The sale of M-Vu Breast Density technology will allow VuCOMP to focus its resources on developing CAD for breast tomosynthesis, President and Chief Technology Officer Jim Pike said in a statement. The firm has filed its premarket approval application for the breast tomosynthesis CAD software with the U.S. Food and Drug Administration and expects to launch the product by the fourth quarter of this year.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
